Pathophysiology, Epidemiology, and Prevention of Pancreatogenic Diabetes - Administrative Supplement

胰源性糖尿病的病理生理学、流行病学和预防 - 行政补充

• 批准号: 9987256
• 负责人: Mark Goodarzi
• 金额: $ 22.08万
• 依托单位: CEDARS-SINAI MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2015
• 资助国家: 美国
• 起止时间: 2015-09-28 至 2020-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9987256
• 关键词: Acute; Administrative Supplement; Adult; Age; Ancillary Study; Childhood; Chronic; Cohort Studies; Collection; Cross-Sectional Studies; Diabetes Mellitus; Diagnosis; Diagnostic; Early Diagnosis; Epidemiology; Etiology; Evaluation; Functional disorder; Future; Goals; Hormones; Infrastructure; Institution; International; Intervention Trial; Malignant Neoplasms; Malignant neoplasm of pancreas; Natural History; Pancreatic Ductal Adenocarcinoma; Pancreatitis; Patient Monitoring; Patients; Pediatrics; Performance; Phenotype; Prevention; Prospective cohort; Recruitment Activity; Recurrence; Relapse; Research Personnel; Resources; Risk; Secondary to; Specimen; Testing; Work; acute pancreatitis; biomarker development; biomarker identification; chronic pancreatitis; cohort; epidemiology study; follow-up; individualized medicine; insight; pediatric patients; prospective; recruit; translational study; working group

This is an application for an administrative supplement for the Cedars-Sinai U01 Center of the Consortium on Chronic Pancreatitis, Diabetes and Pancreatic Cancer (CPDPC) which is led Drs. Pandol and Goodarzi. There has been significant progress within the CPDPC consortium through the efforts of its working groups and committees. However, there are needs to significantly enhance recruitment and monitoring of patients for the cohort studies of CPDCP to meet national goals. The present application provides for plans and resources needed for the Cedars-Sinai U01 Center of the Consortium to make significant contributions to the required national effort. The main goals of the CPDPC are to establish large prospective cohorts of deeply phenotyped patients, with a robust collection of biospecimens for analysis by clinicians and investigators in the future. The cohort studies have been developed by the working groups of the Consortium and include both adult and pediatric patients with proven chronic pancreatitis, suspected or possible chronic pancreatitis, and acute relapsing pancreatitis. These cohorts INSPPIRE2 (INternational Study Group of Pediatric Pancreatitis: In Search for a CuRE) developed by the (CP-RAP) (Chronic Pancreatitis and Recurrent Acute Pancreatitis) Pediatrics Working Group and PROCEED (PROspective Evaluation of Chronic Pancreatitis for EpidEmiologic and Translational StuDies) developed by the CP-RAP Adult Working Group are actively recruiting subjects, and these specimens and cohorts form the platform for future studies defining etiology, diagnostic criteria, natural history, prevention of progression, and individualized therapy in chronic and recurrent acute pancreatitis. A large cohort of patients at increased risk of pancreatic cancer, those with new onset diabetes above the age of 50 (the New-Onset Diabetes [NOD] cohort), developed by the Diabetes and Pancreatic Ductal Adenocarcinoma (DM-PDAC) Working Group is now also recruiting through the CPDPC and other collaborating institutions, with comprehensive collection of biospecimens and follow-up to provide the infrastructure for identification of biomarkers of very early stage, pre-symptomatic pancreatic cancer. As this cancer presents late and remains highly lethal, this work may allow strategies for early detection. Finally, a cross-sectional study (Evaluation of a Mixed Meal Test for Diagnosis and Characterization of PancrEaTogEniC DiabeTes Secondary to Pancreatic Cancer and Chronic Pancreatitis [DETECT]) developed by the Type 3c Diabetes Mellitus (T3cDM) Working Group is identifying the hormones dysregulated in for diabetes associated with chronic pancreatitis and pancreatic cancer, to provide insights into mechanisms and diagnostic criteria for these conditions. Each of these working groups are currently also pursuing numerous synergistic ancillary studies, including studies of etiology, diagnostic performance, biomarker development, mechanistic studies, and intervention trials.

这是慢性病联盟 Cedars-Sinai U01 中心的行政补充申请 胰腺炎、糖尿病和胰腺癌 (CPDPC) 是由 Drs. 领导的。潘多尔和古达尔齐。 通过其工作组和 CPDPC 联盟的努力，CPDPC 联盟已取得重大进展。 委员会。然而，需要显着加强队列患者的招募和监测 研究 CPDCP 以实现国家目标。本申请提供了所需的计划和资源 Cedars-Sinai U01 联盟中心将为所需的国家努力做出重大贡献。 CPDPC 的主要目标是建立深度表型患者的大型前瞻性队列，并具有强大的 收集生物样本供临床医生和研究人员将来进行分析。队列研究已 由该联盟的工作组开发，包括已证实患有慢性疾病的成人和儿童患者 胰腺炎、疑似或可能的慢性胰腺炎和急性复发性胰腺炎。这些群体 INSPPIRE2 （小儿胰腺炎国际研究组：寻找 CuRE）由 (CP-RAP)（慢性胰腺炎）开发 胰腺炎和复发性急性胰腺炎）儿科工作组和 PROCEED（前瞻性评估 慢性胰腺炎流行病学和转化研究）由 CP-RAP 成人工作组织开发 小组正在积极招募受试者，这些标本和队列构成了未来研究定义的平台 慢性病和慢性病的病因、诊断标准、自然史、进展预防和个体化治疗 复发性急性胰腺炎。一大群胰腺癌风险增加的患者，即新发胰腺癌患者 50 岁以上糖尿病（新发糖尿病 [NOD] 队列），由糖尿病和胰腺协会开发 导管腺癌 (DM-PDAC) 工作组目前也在通过 CPDPC 和其他机构招募人员 合作机构，全面收集生物样本并进行后续工作，提供基础设施 用于鉴定极早期、症状前胰腺癌的生物标志物。由于这种癌症出现较晚 并且仍然具有高度致命性，这项工作可能会提供早期发现的策略。最后，进行横断面研究 （混合膳食测试对继发性胰腺病的诊断和表征的评估 胰腺癌和慢性胰腺炎 [DETECT]）由 3c 型糖尿病 (T3cDM) 开发 工作组正在确定与慢性胰腺炎相关的糖尿病相关的激素失调，以及 胰腺癌，以提供对这些疾病的机制和诊断标准的见解。这些中的每一个 工作组目前还在开展大量协同辅助研究，包括病因学研究、 诊断性能、生物标志物开发、机制研究和干预试验。